DOUBLE-BLIND RANDOMISED TRIAL OF ORG 10172 LOW-MOLECULAR-WEIGHT HEPARINOID IN PREVENTION OF DEEP-VEIN THROMBOSIS IN THROMBOTIC STROKE
- 7 March 1987
- journal article
- clinical trial
- Published by Elsevier BV in The Lancet
- Vol. 329 (8532), 523-526
- https://doi.org/10.1016/s0140-6736(87)90173-5
Abstract
No abstract availableKeywords
This publication has 14 references indexed in Scilit:
- A Randomized Controlled Trial of a Low-Molecular-Weight Heparin (Enoxaparin) to Prevent Deep-Vein Thrombosis in Patients Undergoing Elective Hip SurgeryThe New England Journal of Medicine, 1986
- Hemorrhagic doses of heparin and other glycosaminoglycans induce a platelet defectThrombosis Research, 1986
- Efficacy and safety of low-molecular-weight heparin (CY216) in preventing postoperative venous thrombo-embolism: A co-operative studyBritish Journal of Surgery, 1985
- Use of a heparinoid in patients with hemorrhagic stroke and thromboembolic diseaseAnnals of Neurology, 1984
- USE OF A NEW HEPARINOID AS ANTICOAGULANT DURING ACUTE HAEMODIALYSIS OF PATIENTS WITH BLEEDING COMPLICATIONSThe Lancet, 1983
- A novel anti-thrombotic heparinoid (ORG 10172) devoid of bleeding inducing capacity: A survey of its pharmacological properties in experimental animal modelsThrombosis Research, 1982
- The relationship between the hemorrhagic and antithrombotic properties of low molecular weight heparin in rabbitsBlood, 1982
- LOW-DOSE HEPARIN AS A PROPHYLAXIS AGAINST DEEP-VEIN THROMBOSIS AFTER ACUTE STROKEThe Lancet, 1977
- Mortality factors in patients with acute strokeJAMA, 1973
- VENOUS THROMBOSIS FOLLOWING STROKESThe Lancet, 1972